Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BRAF V600E Mutation Clear all
Completed Phase 1 Interventional

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

NCT01791309
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
combination panitumumab and vemurafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

NCT04585815
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Duarte, California • Encinitas, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Results available

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

NCT04462471
View directory record Official record
Conditions
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
Interventions
I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062
View directory record Official record
Conditions
Melanoma
Interventions
GSK1120212, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

NCT01754376
View directory record Official record
Conditions
Melanoma
Interventions
Aldesleukin, Vemurafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 1 Interventional

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160
View directory record Official record
Conditions
BRAF V600 Colorectal Cancer
Interventions
Dabrafenib, LTT462, Trametinib, LXH254, TNO155, Spartalizumab, Tislelizumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

NCT04534283
View directory record Official record
Conditions
Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation
Interventions
Abemaciclib, LY3214996
Drug
Lead sponsor
Anita Turk
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797
View directory record Official record
Conditions
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions
Plixorafenib
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
10 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Encorafenib, Cetuximab, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
View directory record Official record
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

NCT01006980
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib, Dacarbazine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

NCT04620330
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Duarte, California • Aurora, Colorado • Lone Tree, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Vemurafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Early Phase 1 Interventional

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

NCT06610682
View directory record Official record
Conditions
BRAF V600E Mutation
Interventions
Plixorafenib, Retifanlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 1 Interventional

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

NCT04044430
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
Interventions
Binimetinib, Encorafenib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
199
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767
View directory record Official record
Conditions
BRAF V600E Mutation Present, Papillary Craniopharyngioma
Interventions
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
106
States / cities
Birmingham, Alabama • Auburn, California • Berkeley, California + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

NCT01689519
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Placebo, Vemurafenib, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Phase 1 Interventional

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

NCT06902376
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Interventions
Cemiplimab, XL092
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 22, 2026, 2:00 PM EDT